Biological drug duo delivers one-two tumor punch

Jeffrey A. Sosman; James W. Mier

doi:10.1038/nm0603-649

Biological drug duo delivers one-two tumor punch

Jeffrey A. Sosman^*, James W. Mier

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Short survey › peer-review

3 Scopus citations

Abstract

Interleukin (IL)-2 can shrink tumors in patients with refractory melanoma and renal cancer, two of the deadliest types of solid tumors, but the use of IL-2 is limited by its high toxicity. A new drug reduces the side effects in mouse models and boosts the tumor-busting capacity of IL-2.

Original language	English (US)
Pages (from-to)	649-650
Number of pages	2
Journal	Nature Medicine
Volume	9
Issue number	6
DOIs	https://doi.org/10.1038/nm0603-649
State	Published - Jun 1 2003

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nm0603-649

Cite this

@article{d612c3da98684e239243a0596504f1af,

title = "Biological drug duo delivers one-two tumor punch",

abstract = "Interleukin (IL)-2 can shrink tumors in patients with refractory melanoma and renal cancer, two of the deadliest types of solid tumors, but the use of IL-2 is limited by its high toxicity. A new drug reduces the side effects in mouse models and boosts the tumor-busting capacity of IL-2.",

author = "Sosman, {Jeffrey A.} and Mier, {James W.}",

year = "2003",

month = jun,

day = "1",

doi = "10.1038/nm0603-649",

language = "English (US)",

volume = "9",

pages = "649--650",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Biological drug duo delivers one-two tumor punch

AU - Sosman, Jeffrey A.

AU - Mier, James W.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Interleukin (IL)-2 can shrink tumors in patients with refractory melanoma and renal cancer, two of the deadliest types of solid tumors, but the use of IL-2 is limited by its high toxicity. A new drug reduces the side effects in mouse models and boosts the tumor-busting capacity of IL-2.

AB - Interleukin (IL)-2 can shrink tumors in patients with refractory melanoma and renal cancer, two of the deadliest types of solid tumors, but the use of IL-2 is limited by its high toxicity. A new drug reduces the side effects in mouse models and boosts the tumor-busting capacity of IL-2.

UR - http://www.scopus.com/inward/record.url?scp=0037630078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037630078&partnerID=8YFLogxK

U2 - 10.1038/nm0603-649

DO - 10.1038/nm0603-649

M3 - Short survey

C2 - 12778160

AN - SCOPUS:0037630078

SN - 1078-8956

VL - 9

SP - 649

EP - 650

JO - Nature Medicine

JF - Nature Medicine

IS - 6

ER -

Biological drug duo delivers one-two tumor punch

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this